Feasibility study: Results of treatment of primary and recurrent adenocarcinoma of the corpus uteri with Californium-252

Yosh Maruyama, Richard Kryscio, Constance Wood, John R. van Nagell, Elvis Donaldson, Michael Hanson, Justine Yoneda

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


A trial of Cf-252 for the radiotherapy of primary or recurrent corpus adenocarcinoma was carried out at the University of Kentucky. The patients with primary tumors were of advanced age, poor general medical condition, and had multiple chronic medical illnesses, poorly differentiated tumors and/or metastatic Stage IVB disease. Fourteen patients with primary tumors were treated and all achieved complete local tumor control. The five year actuarial disease-free survival rate by the Kaplan-Meier method was 100% for Stage I-III disease, although 36% died of other, usually medical, causes. For eight patients treated with recurrent tumors, long term tumor control was 40% four year actuarial disease survival. Local control was 100% for vault recurrences of 3 cm diameter size, but only 6/8 (75%) cleared their pelvic tumors completely. Those that did not had tumors of massive size, distant metastatic disease and adenosquamous or poorly-differentiated (G3) pattern. One additional cut across, infected tumor was controlled for 26 months. Corpus carcinoma was highly sensitive to Cf-252 neutron radiation therapy.

Original languageEnglish
Pages (from-to)1199-1208
Number of pages10
JournalInternational Journal of Radiation Oncology Biology Physics
Issue number6
StatePublished - Jun 1985

Bibliographical note

Funding Information:
appear in the pelvis and lead to bulky, recurrent central tumors after failure of surgery, with or without prior radiation. The purpose of this paper is to report the results of a clinical feasibility trial using Californium (Cf)-252 to test its efficacy in producing tumor clearance and control for corpus cancer.12 Cf is a transplutonium radioisotope. Californium was discovered in 1950, and it was later discovered that Cf-252 emitted a low energy, fission spectrum of fast neutrons. This led to the study of Cf-252 for human cancer neutron therapy.’ It is potentially useful in intracavitary therapy for gynecological tumors where such therapy has been established to be useful using gamma emitting isotopes such as Ra-266, Cs-137, etc.14 The advantage of Cf-252 over gamma emitting isotopes relate to the fast neutrons where radiobiological studies have shown that the radioresistance of oxygen-deprived (hypoxic) tumor cells can be overcome. Thus, the 3-fold oxygen effect which increases the radioresistance of tumor cells to gamma rays can be reduced to - 1.4 with of Energy. We acknowledge research grant support from the American Cancer Society. We thank Ann Martin, L. C. Wilson, J. M. Feola, J. Sims, J. Sandford, J. L. Beach and C. W. Coffey for assistance in these studies. We thank Mrs. Jean Kennedy for expert secretarial assistance. Accepted for publication 7 January 1985.


  • Cf-252
  • Corpus carcinoma
  • Neutron brachytherapy
  • Primary and recurrent

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Feasibility study: Results of treatment of primary and recurrent adenocarcinoma of the corpus uteri with Californium-252'. Together they form a unique fingerprint.

Cite this